129476-64-8

Usage

Use

Building block in the synthesis of various medications in the pharmaceutical industry

Derivative

Pyrazine

Functional group

Trifluoromethyl group attached to the nitrogen atom

Physical form

White crystalline solid

Solubility

Insoluble in water, soluble in organic solvents

Stability

High stability

Use as reagent

Often used in chemical reactions to introduce the pyrazinylacetamide motif into organic molecules.

InChI:InChI=1/C6H4F3N3O/c7-6(8,9)5(13)12-4-3-10-1-2-11-4/h1-3H,(H,11,12,13)

Upstream product

• 5049-61-6 2-Aminopyrazine 
• 407-25-0 trifluoroacetic anhydride 
• 383-63-1 ethyl trifluoroacetate, 

Downstream Products

• 681249-57-0 2-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine 
• 1575608-05-7 (2R,3R)-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-3-(2-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[1,5-a]piperazine-7(8H)-yl)butan-2-ol 
• 681249-55-8 2,2,2-trifluoro-N’-hydroxy-N-pyrazin-2-ylacetimidamide 

Relevant academic research and scientific papers

Synthesis process of PARP inhibitor fluzopanb intermediate

The invention discloses a process method suitable for large-scale preparation of 2-trifluoromethyl [1,2,4]triazolo[1,5-a] pyrazine, and belongs to the field of drug intermediate synthesis, wherein 2-aminopyrazine and ethyl trifluoroacetate are used as raw materials, and a transesterification reaction, a substitution reaction and a dehydration reaction are performed to obtain 2-trifluoromethyl [1,2,4]triazolo[1,5-a] pyrazine. According to the process disclosed by the invention, cheap ethyl trifluoroacetate is selected to replace expensive trifluoroacetic anhydride, other organic solvents replace a first-class solvent dichloroethane, and TFFA replaces PPA which is difficult to post-treat, so that the production cost of existing biological, medical and chemical intermediates is greatly reduced, amplification verification is conducted on the kilogram-level scale of the process, the yield and the product purity are basically equivalent to those of the gram-level scale, and the process is expected to serve as an industrial large-scale production process.

Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility

Triazoles with fused-heterocycle nuclei were designed and evaluated for their in vitro activity on the basis of the binding mode of albaconazole using molecular docking, along with SAR of antifungal triazoles. Tetrahydro-[1,2,4] triazolo[1,5-a]pyrazine and tetrahydro-thiazolo[5,4-c]pyridine nuclei were preferable to the other four fused-heterocycle nuclei investigated. Potent in vitro activity, broad spectrum and better water solubility were attained when triazoles containing nitrogen aromatic heterocycles were attached to these two nuclei. The most potent compounds 27aa and 45x, with low hERG inhibition and hepatocyte toxicity, both exhibited excellent activity against Candida, Cryptococcus, and Aspergillus spp., as well as selected fluconazole-resistant strains. A high water-soluble compound 58 (the disulfate salt of 45x) displayed unsatisfactory in vivo activity because of its poor PK profiles. Mice infected with C.alb. SC5314 and C.alb. 103 (fluconazole-resistant strain) and administered with 27aa displayed significantly improved survival rates. 27aa also showed favorable pharmacokinetic (PK) profiles.

Design, synthesis, and biological evaluation of triazolopiperazine-based β-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors

Various β-amino amides containing triazolopiperazine heterocycles have been prepared and evaluated as potent, selective, orally active dipeptidyl peptidase IV (DPP-4) inhibitors. These compounds display excellent oral bioavailability and good overall phar

AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to novel substituted aminocyclohexanes which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DPP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

FUSED TRIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to novel fused triazole derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DPP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.